October 2, 2009
By:Ophthalmology Times Staff Reports
The FDA has approved a new drug application (NDA) for ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) as a treatment for acute herpetic keratitis (dendritic ulcers), the company announced.
 |
October 2, 2009
By:Optometry Times Staff Reports
Presbia Coöperatief U.A. of Amsterdam unveiled an implantable micro-lens treatment (Flexivue System) for presbyopia at the European Society of Cataract and Refractive Surgeons annual meeting.
|
October 2, 2009
AMD Alliance International is hosting a video contest to raise awareness for age-related macular degeneration (AMD). Individuals are invited to create and submit videos of no longer than 3 minutes that will communicate in the most creative and visually interesting ways the impact of AMD.
|
September 16, 2009
By:Ophthalmology Times Staff Reports
LenSx Lasers Inc. announced that the FDA has granted 510(k) clearance for its femtosecond laser used for anterior capsulotomy during cataract surgery.
|
September 16, 2009
Corneal cross-linking (CXL) can help treat corneal melting, said Theo Seiler, MD, PhD.
|
September 16, 2009
Sirion Therapeutics Inc. announced the FDA approval of its new drug application for ganciclovir ophthalmic gel 0.15% (Zirgan) as a treatment for acute herpetic keratitis. The FDA granted orphan drug designation to the gel for this indication in April 2007.
|
September 16, 2009
Surgeons should not use home-made solutions or riboflavin in their corneal cross-linking technique, as it leads to unreliable results, said Paolo Vinciguerra, MD.
|
September 16, 2009
The next steps in the evolution of corneal cross linking (CXL) therapy must seek to improve the penetration of riboflavin to the deepest corneal layers, said Jesper Hjortdal, MD, PhD.
|
| 
Practice Tools
